Cat. No.: HY-106382

PMEDAP

Customer Review

Based on 1 Customer Validation

PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication. PMEDAP has anti-murine cytomegalovirus (MCMV) activity. PMEDAP is a very potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality.

For research use only. We do not sell to patients.

Purity: 98.0%
CAS No.: 113852-41-8
Formula: C₈H₁₃N₆O₄P
Molecular Weight:288.20

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

PMEDAP Chemical Structure

CAS No.: 113852-41-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-HSB-2	CC₅₀	>56 μM Compound: PME-DAP	Cytotoxicity against human HSB2 cell after 4 hrs by MTS assay Cytotoxicity against human HSB2 cell after 4 hrs by MTS assay	[PMID: 18852272]
Daudi	CC₅₀	>50 μM Compound: PME-DAP	Cytotoxicity against human Daudi cell after 4 hrs by MTS assay Cytotoxicity against human Daudi cell after 4 hrs by MTS assay	[PMID: 18852272]
HEL	EC₅₀	>50 μM Compound: PMEDAP	Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	0.82 μM Compound: PMEDAP	Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	1.6 μg/mL Compound: PMEDAP	Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	1.9 μM Compound: PMEDAP	Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	12 μg/mL Compound: PMEDAP	Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	2.8 μg/mL Compound: PMEDAP	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	25 μM Compound: PMEDAP	Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	26 μg/mL Compound: PMEDAP	Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	3.5 μM Compound: PMEDAP	Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	37 μM Compound: PMEDAP	Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	38 μg/mL Compound: PMEDAP	Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	44 μg/mL Compound: PMEDAP	Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	5.2 μg/mL Compound: PMEDAP	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	6.7 μg/mL Compound: PMEDAP	Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	7.7 μM Compound: PMEDAP	Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	8.4 μM Compound: PMEDAP	Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL 299	CC₅₀	100 μM Compound: 3b, PMEDAP	Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis	[PMID: 17893157]
HEL 299	EC₅₀	>173 μM Compound: 3b, PMEDAP	Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HEL 299	EC₅₀	>173 μM Compound: 3b, PMEDAP	Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining	[PMID: 17893157]
HFF	CC₅₀	>100 μM Compound: PME-DAP	Cytotoxicity against human HFF cells after 7 days by neutral red dye method Cytotoxicity against human HFF cells after 7 days by neutral red dye method	[PMID: 18852272]
HFF	CC₅₀	170 μM Compound: PME-DAP	Cytotoxicity against human HFF cells Cytotoxicity against human HFF cells	[PMID: 18852272]
HFF	EC₅₀	>10 μM Compound: PME-DAP	Antiviral activity against herpes simplex virus 1 E-377 infected in HFF cells by plaque reduction assay Antiviral activity against herpes simplex virus 1 E-377 infected in HFF cells by plaque reduction assay	[PMID: 18852272]
HFF	EC₅₀	>10 μM Compound: PME-DAP	Antiviral activity against herpes simplex virus 2 MS infected in HFF cells by plaque reduction assay Antiviral activity against herpes simplex virus 2 MS infected in HFF cells by plaque reduction assay	[PMID: 18852272]
HFF	EC₅₀	0.2 μM Compound: PME-DAP	Antiviral activity against Murine cytomegalovirus Smith infected in HFF cells by plaque reduction assay Antiviral activity against Murine cytomegalovirus Smith infected in HFF cells by plaque reduction assay	[PMID: 18852272]
HFF	EC₅₀	13 μM Compound: PME-DAP	Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells by plaque reduction assay Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells by plaque reduction assay	[PMID: 18852272]
HFF	EC₅₀	2.9 μM Compound: PME-DAP	Antiviral activity against Varicella zoster virus Ellen infected in HFF cells by plaque reduction assay Antiviral activity against Varicella zoster virus Ellen infected in HFF cells by plaque reduction assay	[PMID: 18852272]
MOLT-3	CC₅₀	39 μM Compound: PME-DAP	Cytotoxicity against human MOLT3 cell after 4 hrs by MTS assay Cytotoxicity against human MOLT3 cell after 4 hrs by MTS assay	[PMID: 18852272]
MOLT-3	EC₅₀	28 μM Compound: PME-DAP	Antiviral activity against Human herpesvirus 6B Z29 infected in human MOLT-3 cells Antiviral activity against Human herpesvirus 6B Z29 infected in human MOLT-3 cells	[PMID: 18852272]
MT4	EC₅₀	2.67 μg/mL Compound: 23b	Inhibitory activity of compound against human immunodeficiency virus type 1 (HIV-1) induced cytopathogenicity in MT-4 cells Inhibitory activity of compound against human immunodeficiency virus type 1 (HIV-1) induced cytopathogenicity in MT-4 cells	[PMID: 10377214]
MT4	IC₅₀	1 μM Compound: 4 (PMEDAP)	The compound was evaluated for its ability to Inhibit HIV replication in MT-4 cells The compound was evaluated for its ability to Inhibit HIV replication in MT-4 cells	10.1016/S0960-894X(01)80206-7

In Vivo

PMEDAP (0.25-5 mg/kg; IP; daily; starting on the day of MSV-infected and continuing for an additional four days) causes a dose-dependent suppression of tumor formation and mortality in newborn mice inoculated with MSV^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Three-week-old male NMRI mice^[1]
Dosage:

0.25 mg/kg, 1 mg/kg, 5 mg/kg
Administration:

IP; daily; starting on the day of infection and continuing for an additional four days
Result:

Effected a significant delay in tumor appearance and an enhancement of the survival rate of tumor-bearing mice.

Chemical Information

CAS No. 113852-41-8
Appearance Solid
Molecular Weight 288.20
Formula C₈H₁₃N₆O₄P
Color White to off-white
SMILES

O=P(O)(COCCN1C=NC2=C1N=C(N)N=C2N)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

0.1 M NaOH : 14.29 mg/mL (49.58 mM; ultrasonic and adjust pH to 12 with NaOH)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4698 mL

17.3491 mL

34.6981 mL

5 mM

0.6940 mL

3.4698 mL

6.9396 mL

10 mM

0.3470 mL

1.7349 mL

3.4698 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Neyts J, et al. Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo [published correction appears in Eur J Clin Microbiol Infect Dis 1993 Jul;12(7):following 477]. Eur J Clin Microbiol Infect Dis. 1993;12(6):437-446. [Content Brief]

[2]. Naesens L, et al. 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis. 1989;8(12):1043-1047. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
0.1 M NaOH	1 mM	3.4698 mL	17.3491 mL	34.6981 mL	86.7453 mL
	5 mM	0.6940 mL	3.4698 mL	6.9396 mL	17.3491 mL
	10 mM	0.3470 mL	1.7349 mL	3.4698 mL	8.6745 mL
	15 mM	0.2313 mL	1.1566 mL	2.3132 mL	5.7830 mL
	20 mM	0.1735 mL	0.8675 mL	1.7349 mL	4.3373 mL
	25 mM	0.1388 mL	0.6940 mL	1.3879 mL	3.4698 mL
	30 mM	0.1157 mL	0.5783 mL	1.1566 mL	2.8915 mL
	40 mM	0.0867 mL	0.4337 mL	0.8675 mL	2.1686 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PMEDAP

MCE Bioactive Compound Library

All HIV Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

PMEDAP Related Classifications

HY-106382 Related Classifications